Martin Everett


Martin has over 25 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, Antabio). At GSK he worked in anti-tubercular target development before managing an automated high-throughput screening group and leading several antibacterial and oncology lead discovery projects. At MerLion he was Head of Research leading a multi-disciplinary team discovering and developing novel natural product derived compounds and working on development of the fluoroquinolone antibiotic Finafloxacin. He is an author on over 25 publications in peer reviewed journals. At Antabio, Martin is the CSO, leading the R&D team and is PI for the PEI program.